JP2013519699A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519699A5
JP2013519699A5 JP2012553267A JP2012553267A JP2013519699A5 JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5 JP 2012553267 A JP2012553267 A JP 2012553267A JP 2012553267 A JP2012553267 A JP 2012553267A JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5
Authority
JP
Japan
Prior art keywords
molecule
domain
fviii
another embodiment
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012553267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051959 external-priority patent/WO2011101284A1/en
Publication of JP2013519699A publication Critical patent/JP2013519699A/ja
Publication of JP2013519699A5 publication Critical patent/JP2013519699A5/ja
Withdrawn legal-status Critical Current

Links

JP2012553267A 2010-02-16 2011-02-10 因子viii融合タンパク質 Withdrawn JP2013519699A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153715 2010-02-16
EP10153715.7 2010-02-16
US30617710P 2010-02-19 2010-02-19
US61/306,177 2010-02-19
PCT/EP2011/051959 WO2011101284A1 (en) 2010-02-16 2011-02-10 Factor viii fusion protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016021624A Division JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質

Publications (2)

Publication Number Publication Date
JP2013519699A JP2013519699A (ja) 2013-05-30
JP2013519699A5 true JP2013519699A5 (enExample) 2015-07-02

Family

ID=42244627

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012553267A Withdrawn JP2013519699A (ja) 2010-02-16 2011-02-10 因子viii融合タンパク質
JP2016021624A Expired - Fee Related JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質
JP2017144266A Withdrawn JP2017190342A (ja) 2010-02-16 2017-07-26 因子viii融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016021624A Expired - Fee Related JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質
JP2017144266A Withdrawn JP2017190342A (ja) 2010-02-16 2017-07-26 因子viii融合タンパク質

Country Status (5)

Country Link
US (2) US9493543B2 (enExample)
EP (2) EP2536754A1 (enExample)
JP (3) JP2013519699A (enExample)
CN (2) CN102770450B (enExample)
WO (1) WO2011101284A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
JP5914363B2 (ja) * 2010-02-16 2016-05-11 ノヴォ ノルディスク アー/エス 低減されたvwf結合を有する因子viii分子
EP2804623B1 (en) * 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) * 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
WO2013160005A1 (en) 2012-04-24 2013-10-31 Novo Nordisk A/S Pharmaceutical composition suitable for treatment of haemophilia
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
JP6618892B2 (ja) 2013-04-23 2019-12-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 細菌バイオフィルムの遺伝的リプログラミング
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子viii-xten融合物及其用途
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
EP3114138B1 (en) * 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第viii因子製剤
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
WO2016164422A2 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
WO2016198521A1 (en) * 2015-06-10 2016-12-15 Novo Nordisk A/S Fviii fusion proteins
CN104926946B (zh) * 2015-07-13 2021-09-17 中国科学院广州生物医药与健康研究院 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
EP3334452A4 (en) 2015-08-12 2019-04-17 Cell Machines, Inc. METHOD AND COMPOSITIONS IN CONJUNCTION WITH COMBUSTION COMPLEXES WITH LONG HALF TIME
GB201520021D0 (en) * 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技(上海)有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技(上海)有限公司 人白介素7融合蛋白及其制备方法
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技(上海)有限公司 用于构建融合蛋白的连接肽
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CN108623695B (zh) * 2017-03-24 2022-03-15 中国科学院过程工程研究所 一种白蛋白结合肽-人睫状神经营养因子融合蛋白及其制备方法和应用
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019219048A1 (zh) * 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 具有延长半衰期的融合多肽缀合物
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
WO2019219049A1 (zh) * 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 改进的fviii融合蛋白及其应用
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技(上海)有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
EP4017521A1 (en) * 2019-09-02 2022-06-29 Biotest AG Factor viii protein with increased half-life
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
CN114901671B (zh) * 2020-01-20 2024-02-20 上海药明生物技术有限公司 用于亲和层析的新的清洗缓冲溶液
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
IL301332A (en) * 2020-09-23 2023-05-01 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
EP4534563A1 (en) * 2022-05-25 2025-04-09 Jiangsu Gensciences Inc. Fviii fusion protein conjugate having extended half-life and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3879395T2 (de) 1987-05-29 1993-06-24 Central Glass Co Ltd Fusionsprotein, enthaltend lymphotoxin.
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US6939677B1 (en) 1990-11-01 2005-09-06 Cancer Research Fund Of Contra Costa Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6524572B1 (en) 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20070106066A1 (en) 2003-10-28 2007-05-10 Alexander Cherkasky Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions
US20070275873A1 (en) 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
WO2006102652A2 (en) 2005-03-24 2006-09-28 Neose Technologies, Inc. Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007065691A2 (en) 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
US20090053790A1 (en) 2006-01-31 2009-02-26 Ishihara Sangyo Kaisha, Ltd. Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
WO2008068280A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
CA2676098A1 (en) * 2007-01-23 2008-07-31 Zymogenetics, Inc. Soluble fcgammaria and related methods
US8043621B2 (en) 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
AU2008314697B2 (en) 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
DK2257311T3 (da) * 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
DK2865760T3 (en) * 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life

Similar Documents

Publication Publication Date Title
JP6559642B2 (ja) Fviiiの特定部位の変更
JP6527918B2 (ja) 第viii因子組成物、ならびに組成物の作製方法および用途
JP2018104459A (ja) 血友病の治療に適する化合物
JP2017503509A5 (enExample)
JP6605593B2 (ja) 第viii因子およびフォン・ヴィルブランド因子ペプチドを含む製剤
JP2015527882A5 (enExample)
JP2016522219A (ja) 血友病の治療に適する化合物
JP2015519313A (ja) 血友病の治療に適する医薬組成物
JP2023134586A (ja) Siglec依存的免疫応答をモジュレートするポリペプチド
JP2005535588A (ja) 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
WO2020063562A1 (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
JP2024526356A5 (enExample)
WO2017050820A1 (en) Fviii fusion proteins
JP2026513540A (ja) 薬物動態が改善されたfviii-vwf融合タンパク質